Jenscare Scientific Co., Ltd. announced that Professor Ge Junbo from Zhongshan Hospital affiliated to Fudan University ("Fu Dan Da Xue Fu Shu Zhong Shan Yi Yuan") and his team will give a report on the results of the multicenter clinical trial of LuX-Valve Plus at the 2023 Transcatheter Cardiovascular Therapeutics conference ("TCT") in the U.S. LuX-Valve Plus is the second-generation transjugular vein tricuspid valve replacement system independently developed by the Company. The 2023 TCT will be held in San Francisco, California, the U.S. from October 23, 2023 to October 26, 2023. The TCT is the annual scientific symposium held by the Cardiovascular Research Foundation ("CRF") and is the largest and most influential global conference focusing on cardiovascular interventional medicine in the world.

The company actively promoting the clinical trials for CE Certificate in Europe, the clinical trials for FDA registration in the U.S. and the fee-for-service compassionate treatment in the Asia-Pacific region of LuX-ValvePlus. The shareholders of the Company and potential investors can refer to Professor Ge Junbo's speech at the 2023 TCT to obtain more information about this product and its clinical research.